

ASX Announcement

Appendix 3Y – Nicholas Hartnell

SYDNEY 26 August 2022 – Allegra Orthopaedics Limited (Allegra) (ASX:AMT) advises of the late lodgment of the attached Appendix 3Y for the acquisition of 10,000 fully paid ordinary shares by Mr Nicholas Hartnell.

In relation to the late lodgment of the attached Appendix 3Y, Allegra advises as follows:

- (a) The change that occurred related to the issue of 10,000 fully paid ordinary shares subsequent to an on-market purchase by Mr Hartnell;
- (b) The Appendix 3Y was lodged late due to an administrative oversight. As soon as the oversight was identified, the attached Appendix 3Y was prepared and lodged with the ASX. The Company considers the late lodgment of this Appendix 3Y to be an isolated incident;
- (c) The Company and the Directors are aware of their obligation under Listing Rules 3.19A and 3.19B to provide the necessary information to the Company to meet its disclosure requirements;
- (d) The Company is committed to maintaining a high standard of corporate governance practices and ensuring its compliance with the ASX Listing Rules. Allegra is confident that the processes it has in place will ensure compliance with Listing Rules 3.19A and 3.19B.

This announcement has been authorised for release by the Company Secretary.

Contact details:

Robyn Slaughter
Company Secretary
D: +61 2 8072 1435

ABOUT ALLEGRA ORTHOPAEDICS:

We aim to help bring the freedom and happiness of pain-free movement to people's lives. We achieve this through providing the best possible solutions for patients, from world-wide industry leading orthopaedic products through to Australian innovations. Allegra's principal product, the Active Total Knee, has significantly improved the quality of life for many people and remains a focused product line. Allegra is also the exclusive distributors of Waldemar Link GmbH & Co. KG products in Australia. Link consists of a range of complex lower limb, hip and knee replacements, including oncology solutions. The Link products add to Allegra's well-developed range of products for distribution from international suppliers covering all specialties from foot and ankle to upper limb. The company is pleased to continue to build upon its extensive portfolio of patents. It has strong research relationships with universities, companies and surgeon inventor.

Allegra Orthopaedics Limited

Level 8, 18 --- 20 Orion Rd, Lane Cove West NSW 2066 Australia; PO Box 72 St Leonards NSW 2065 Australia

T +612 9119 9200 **T** Toll Free 1800 644 370

F +612 9439 4441 **F** Toll Free 1800 624 223

E sales@allegraorthopaedics.com

www.allegraorthopaedics.com

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Allegra Orthopaedics Limited
ABN	066 281 132

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Nicholas Hartnell
Date of last notice	4 November 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect & Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Robinwood Investments Pty Ltd, an entity controlled by Nicholas Hartnell
Date of change	2 June 2020
No. of securities held prior to change	<u>Direct</u> 1,214,090 Fully Paid Ordinary Shares 3,000,000 Unlisted Options <u>Indirect</u> 38,274,948 Fully Paid Ordinary Shares
Class	Fully Paid Ordinary Shares
Number acquired	10,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.11 per share

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<u>Direct</u> 1,224,090 Fully Paid Ordinary Shares 3,000,000 Unlisted Options <u>Indirect</u> 38,274,948 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On market movement

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If prior written clearance was provided, on what date was this provided?	N/A
--	-----

+ See chapter 19 for defined terms.